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Abstract: The pathophysiology of atopic dermatitis (AD) is multifactorial and is a complex
interrelationship between skin barrier, genetic predisposition, immunologic development, skin
microbiome, environmental, nutritional, pharmacological, and psychological factors. Several
microbial modulations of the intestinal microbiome with pre- and/or probiotics have been used in
AD management, with different clinical out-come (both positive, as well as null findings). This review
provides an overview of the clinical evidence from trials in children from 2008 to 2017, aiming to
evaluate the effect of dietary interventions with pre- and/or pro-biotics for the treatment of AD.
By searching the PUBMED/MEDLINE, EMBADE, and COCHRANE databases 14 clinical studies
were selected and included within this review. Data extraction was independently conducted by two
authors. The primary outcome was an improvement in the clinical score of AD severity. Changes
of serum immunological markers and/or gastrointestinal symptoms were explored if available.
In these studies some dietary interventions with pre- and/or pro-biotics were beneficial compared
to control diets in the management of AD in children, next to treatment with emollients, and/or
local corticosteroids. However, heterogeneity between studies was high, making it clear that focused
clinical randomized controlled trials are needed to understand the potential role and underlying
mechanism of dietary interventions in children with AD.
Keywords: atopic dermatitis; children; mucosal immune development
1. Introduction
Worldwide, the most common inflammatory skin disease is atopic dermatitis (AD) with
a prevalence of 10–20% in children [1]. In 60% of these children, the onset of AD occurs early in life,
before one year of age [2]. Pediatric AD can be characterized by its relapsing-remitting nature and the
overall severity is mild in most of these young children [3]. The pathophysiology is multifactorial with
a complex interrelationship between skin barrier development, genetic predisposition, immunological
development, skin microbiome composition, and environmental, nutritional, pharmacological, and
psychological factors. Whether or not AD is a primarily driven barrier dysfunction or a primarily
inflammatory skin disease remains open for debate. Taking into account the recent understanding of
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the complex role of host microbial development in early life, new insights on regarding the role of
microbial modulation in AD development during infancy may be hypothesized.
1.1. Host–Microbiome Development and Nutrition
The first contact of mucosal tissues to external microbiota is crucial in the establishment and
maturation of the mucosal, as well as systemic, immune systems [4,5]. In particular, the first year of
life is essential for programming the immune system. The development of barrier function and the
immune system are influenced by environmental factors, such as feeding patterns, antibiotic use by
the mother during delivery, or postnatal use of antibiotics by the neonate [6]. Proper understanding
of the protective and programming effects of a healthy immune and microbiome development may
provide opportunities to reduce the risk of development of AD. Any discordance between the early
developmental requirements of the infant’s immune system may contribute to the development of
allergic diseases [7]. A recent COCHRANE systematic review of five clinical trials (952 participants)
concluded that avoiding major allergens in the maternal diet (during gestation/lactation) does not
protect against development of AD in the infant during the first 18 months of life [8]. This study also
concluded that there was insufficient evidence that prolonged exclusive breast feeding was protective
against AD. Early sensitization to food allergens through breast milk, skin contact, and/or inhalation
occurs and may explain why some infants show an allergic response to specific proteins despite having
never ingested it [7]. An additional influencing factor in allergy development is the timing of solid food
introduction. For instance, infants starting with solid food introduction at four or five months of age
had a lower risk for AD development (Odds ratio = 0.41, 95% Confidence interval, 0.20–0.87) compared
to infants which were exclusively breastfed [9]. However, except maybe for peanut allergy, strong
evidence is lacking to decide whether the age of complementary food introduction should be four or
six months in order to prevent the development of allergy [5]. Although scientific evidence is limited,
it has been suggested that timing of the start and type of nutrition (i.e., breastfeeding/infant formula)
during solid food introduction influences the development of allergic diseases [10]. The question,
however, remains whether observed effects are derived from direct interaction with immune cells,
or indirectly through alterations in the microbiome composition and change in derivatives thereof,
followed by immune changes [11]. The microbial composition is involved in the development of
the regulatory T cell response and thereby plays a key role in immune development [12]. Within
in vitro assays it has been shown that the addition of specific oligosaccharides during dendritic cell
development induces a regulatory T cell response potentially of benefit in an allergic setting [13].
Moreover, dietary supplementation with specific prebiotic oligosaccharides has been shown to reduce
the risk of developing allergies in infants [14]. Therefore, during early life it seems likely that specific
components can contribute to the normal immune development via multiple direct and indirect
pathways, thereby reducing the risk of allergic manifestations.
1.2. Development of Skin and Microbiome in Early Life
The composition and diversity of the skin microbiome shows a unique habitat per location,
especially within children. The skin microbiome composition may be affected by different factors
including age, sex, and microbial antigen exposure. Skin microbiota of neonates varies by the mode of
delivery, but the differences become less apparent with age in early childhood [15,16]. The composition
is also dependent on pH, temperature, Ultraviolet (UV) exposure, natural moisturizing factors (NMFs),
and can easily change over time [17]. Specific changes in the skin microbiome have been associated
with AD and other allergic manifestations [18]. AD has been associated with early life colonization
of Staphylococcus aureus (S. aureus). A reduced bacterial diversity in the skin microbiome is of major
importance in AD pathogenesis [19]. Only 5% of the skin microbiome in non-atopic individuals
is colonized with S. aureus, compared to 39% in non-lesional skin and 70% in lesional skin of AD
patients [20,21]. Although within a birth cohort it was shown that 10 infants with AD at the age of
12 months were not colonized with S. aureus before their first AD manifestation [22], colonization and
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infection with S. aureus has been associated with increased IgE responses, food allergy, and severity
of AD skin disease [23,24]. In addition to the bacterial composition, the fungal and viral community
differences are also associated with allergic manifestations such as rhinitis and asthma, as well [25,26].
This underscores the complexity of the host-microbe balance induction, as well as the sensitivity
towards modulations herein [27].
Although whether or not AD is primarily driven by microbial dysbiosis leading to barrier
dysfunction remains a key question, the skin barrier is hampered in AD. Within infants the skin
has a higher ability to restore itself as a barrier. This adaptive flexibility results in unique properties of
infant skin [28]. In a recent meta-analysis of genome-wide association studies of more than 15 million
genetic variants in 21,399 cases and 95,464 controls, 10 new loci associated with AD risk were identified,
bringing the total susceptibility loci until to 31 at the time of this publication [28–30]. Children
with AD have changes in their skin barrier due to filaggrin deficiency or tight-junction dysfunction,
which allows the penetration of irritants, allergens, and bacteria, leading to inflammation [31,32].
1.3. Immune Deregulation within AD
In AD, the skin barrier function is compromised, allowing penetration of environmental factors,
such as irritants, allergens, and bacteria, leading to inflammation and/or allergic sensitization [33,34].
Skin barrier dysfunction induces the release of several inflammatory factors, including thymic stromal
lymphopoietin (TSLP) and other cytokines and chemokines, which trigger inflammation in the skin [35].
These pro-inflammatory mediators (including chemokines) are released by the affected keratinocytes
to attract leukocytes to the site of inflammation [36,37]. The characteristic leukocyte migration into
the skin is driven by excessive chemokine production at the site of inflammation. Several chemokines
(classically characterized within the Th1-type of response: CXCL9, CXCL10, and CXCL11; the Th2-type
response: CCL-17, CCL22; and for inflammation: CCL-20) have been associated with an AD phenotype
comprising complex pathology [38]. Studies on the pathology of early paediatric AD are limited and
correlation of disease activity has been shown with only a few serum biomarkers (i.e., CCL17, CCL22,
CCL27, and IgE) in infants [38,39]. Recently, profound immune activation in non-lesional skin in
paediatric patients with AD has also been detected [38]. While little is known about the alterations
in skin-derived immunity and skin barrier function that occur during the early-onset phase of AD,
Th2 (IL-13, IL-31, and CCL17), Th22 (IL-22 and S100As), and some Th1-skewing (IFN-γ and CXCL10)
have been detected in the skin, which is also observed in adults [38]. An increase in recruited Th2
cell populations classically leads to the increased production of interleukins IL-4, IL-5, and IL-13,
which may be locally involved in the induction of IgE and eosinophil activation [39]. However,
the identification of the trigger in AD development is still very complex.
1.4. Current Understanding in the Specific Microbial Modulations in AD
Due to the potential role of the microbiome in children with AD and development in early
childhood, this seems a promising time frame for effective nutritional interventions including those
with pre- and/or probiotics. In 2008 a comprehensive COCHRANE review (analysing 10 clinical trials
(up to April 2008 (781 children)) concluded that overall probiotics in general seem not to be effective
as a treatment of AD [40]. On the contrary, a modest role for probiotic interventions in paediatric
dermatitis was suggested [41,42], as well as within later studies regarding pre- and/or probiotic
interventions [43]. As stated by the recent meta-analysis by Kim et al. [44], the difference between
age and severity of AD as measured by scoring of childhood atopic dermatitis (SCORAD) should
be taken into account when analysing the impact of microbial modulations. Collectively, there was
a large heterogeneity between trials complicating the comparison between specific species, strains,
dosage, duration, time or age, and clinical outcomes. The aim of this review is to give an overview of
the results of recently performed clinical intervention studies published after the COCHRANE review
in 2008 until June 2017, studying the effect of microbial modulations for treatment of AD in children.
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2. Methods
2.1. Search Strategy
To identify clinical dietary intervention studies with prebiotics/probiotics and/or synbiotics
in children with AD, from birth up to 18 years of age, the PUBMED/MEDLINE, EMBASE,
and COCHRANE databases have been searched. Since the COCHRANE review included all clinical
trials up to April 2008, the literature search started from 2008 to June 2017. The following keywords
were used: (probiotics OR prebiotics OR synbiotics) AND (atopic dermatitis OR eczema).
2.2. Study Selection
Published clinical intervention studies were included within this review meeting the following
criteria: clinical studies with a dietary intervention with prebiotic(s) and/or probiotic(s), all participants
were human, more specifically children from birth up to 18 years of age, all children with AD before
the start of intervention, only studies with a clinical outcome for AD severity, studies published in
the last 10 years, written in English, and presenting original data. A total of 75 abstracts have been
retrieved through the database searches. Two authors independently checked the fulfilment of the
inclusion criteria for this review by screening titles and abstracts and excluded studies that obviously
did not fulfil the inclusion criteria. Seventy-three were published between April 2008 and 2017. A total
of 59 from the 73 studies were excluded for this review, due to different outcomes than the inclusion
criteria for this overview. The majority of these clinical studies had prevention of AD or other allergic
manifestations as the primary outcome (N = 31). Other reasons to exclude studies were: no clinical
AD outcome value, only gastrointestinal outcomes, safety studies, or genetic outcomes. In addition,
three long-term follow-up studies were excluded. Finally the reference lists of the positively identified
articles were checked for additional clinical studies and led to one additional study.
2.3. Data Extraction
Data extraction was independently conducted by two authors and cross-checked to avoid errors.
Disagreements were resolved through consensus and, when needed, using the opinion of a third
author. Details of the study were recorded: methods, objectives, study population, age of children
with AD, inclusion and exclusion criteria, mild-to moderate-to severe AD, mean SCORAD scores,
specific dietary intervention, strain and dosage of prebiotics and or probiotics, control diet, duration
of intervention, number of randomized children in each group, clinical outcome of AD severity and
change in AD severity (using primarily the AD scoring system SCORAD [45]). In addition, if available,
the immunological outcomes, as well as the gastrointestinal outcomes, were included.
3. Results
3.1. Study Characteristics
The literature search resulted in 75 clinical intervention studies and, after inclusion, 13 studies
could be used. One publication included two different types of interventions; open label versus
randomized control using the same probiotic strain. Therefore, those two clinical studies will be
mentioned separately in this overview. The study characteristics of the 14 selected clinical trials
(N = 1008 children with AD) are summarized in Table 1 [43,46–57].
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The clinical dietary intervention studies have been ordered according to the age of the children at inclusion. Abbreviations Table 1: AD, atopic dermatitis; IgE, Immunoglobulin
E; HA, hydrolysed infant formula; GOS, galacto-oligosaccharides; SCORAD, scoring atopic dermatitis score; FOS, Fructo-oligosaccharides; BB, Bifidobacterium breve M-16V; CFU,
colony-forming units; LP, Lactobacillus paracasei CNCMI-2116; BL Bifidobacterium lactis CNCMI-3446; C, control group; DBPCFC, double blind placebo controlled food challenge; LA,
Lactobacillus achidophilus DDS-1, BL2 Bifidobacterium lactis UABLA-12; LS Lactobacillus salivarius LS01 DSM22775; LP2, Lactobacillus plantarum CJLP133; LP3, Lactobacillus para-casei GMNL-133;
LF, Lactobacillus fermentum GM090; LS2 Lactobacillus sakei KCTC10755BP; LS3, Lactobacillus salivarius PM-A0006; LR, Lactobacillus reuteri ATCC55730; LA2, Lactobacillus acidophilus L-92.
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3.2. Specific Dietary Intervention
Since the results of clinical intervention studies in the past showed inconclusive results of
prebiotics and/or probiotics in the treatment of AD, it was hypothesized that the beneficial effects of
prebiotics and probiotics are strain- and dose-dependent. Lactobacillus and Bifidobacterium are the two
most investigated bacterial species in allergy research. Again, a wide variety in the dietary intervention
studies was found in the clinical trials between 2008 and 2017 (Table 1). In total, 12 included trials
were randomized controlled trials (RCTs) which had a total of 601 AD children in the treatment
groups and 444 AD children in the control groups. The two additional clinical trials provided
an open label intervention and were conducted with 63 children with AD. Not one intervention
study used the same strain of probiotics or the same combination with prebiotics. More specifically,
five RCTs provided synbiotic mixtures [43,47,49,50,55], four RCTs provided only one probiotic as
dietary intervention [52,54,56,57], two RCTs provided more than one probiotic strain within the
study [48,53], one trial explored the effect of prebiotics only [46], and the two open label studies were
conducted with only one probiotic strain [51,57].
3.3. Effect of Dietary Intervention on Clinically-Detected AD Severity
In total, 12 out of the 14 studies reported the severity in AD using SCORAD. Three of the five
RCTs with synbiotic intervention showed significant AD improvement by reduction of AD severity
after dietary intervention compared to control diet [49,50,55]. The remaining two synbiotic RCTs
showed a significant reduction of SCORAD score in both groups [43,47]. Improvement of AD severity
was shown in three out of the four RCTs with one probiotic strain [52,54,57]. In addition, the result
of the two open label intervention studies with one strain of probiotics is an improvement in AD
symptoms [51,57]. Additionally, the RCT with the highest enrolment of children with AD (N = 220),
showed an improvement in AD severity compared to the control group [53]. The trial of Gore et al.
with two strains of probiotics showed a reduction of the SCORAD score in both groups [48]. The
prebiotic trial showed improvement of AD severity in both groups [46]. In addition, the RCT with
synbiotic intervention showed improvement of AD severity (SCORAD score). In the trial of van der
Aa et al., a subgroup analysis of AD infants with elevated IgE levels showed a greater SCORAD score
reduction in the synbiotic group [43]. A previous study also showed that synbiotic interventions
may have beneficial effects, especially in AD with elevated IgE [58]. Taking IgE further into account,
Shafiei et al. found no differences in comparing SCORAD scores in the IgE and non-IgE AD infants [47].
In contrast to Wang et al., who included only AD children with at least one positive skin prick test or
at least one elevated specific IgE level within their study, showed improvement in AD [53], suggesting
an important role for IgE.
3.4. Additional Effect of Dietary Interventions
Knowing the complexity of development in early life, some studies provide additional exploratory
markers within the different RCTs. Three RCTs showed changing levels in cytokines IL-4 and/or IFN-y,
which were significantly lower after intervention or did not show any change [51–53]. Additionally,
changes in serum chemokine markers were detected, showing significant changes in two [54,57]
groups, and no significant differences between groups in another study [43]. Some studies showed
changes in IgE levels, but no significance between treatment and control [43,48,53]. In addition to
serum markers, a few studies provide additional data on the effect of dietary intervention cellular
composition [50]. For instance, the eosinophil count was significantly lower between groups in one
study [52], and over time in one other study [55]. In three studies no immunological data was available,
which may be due to the young age of infants included in those studies [46,47,51]. Only three RCTs
reported on faecal bacterial counts after dietary intervention; all, however, confirmed changes in gut
microbial composition after dietary intervention. Gastrointestinal symptoms, such as stool consistency
and diaper dermatitis, were also positively influenced in the treatment group compared to control
after the specific dietary interventions [43,46].
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3.5. Treatment Duration and Time of Intervention
Within the identified clinical intervention studies, the treatment duration was variable, ranging
from eight weeks up to six months [43,46–57]. There seemed to be no association between the
duration of dietary intervention and the outcome of clinical improvement of AD. The trials indicating
improvement of AD in both groups had intervention periods of eight or 12 weeks [43,46,48].
The effective duration of dietary intervention remains unclear. In two trials included in this review,
a positive beneficial effect on AD severity remained detectable after the intervention period [53,55].
4. Discussion
This review summarizes the clinical outcome on AD severity among children receiving dietary
intervention with or without prebiotics, probiotics, or synbiotics. It presents an overview of data from
2008 to June 2017 regarding the use of the specific dietary interventions in the treatment of AD in
children, from birth up to 18 years of age available to date. As in earlier studies and meta-analyses
published up to 2008, overall, strong evidence to clarify insights into the role of pre-, pro-, and
synbiotics in treatment of AD is lacking, which may be due to high heterogeneity among the trials.
Moreover, the outcome on AD severity seems to depend of multiple factors, including age, season, UV
exposure, the use of local corticosteroids, number of AD exacerbations, etc.
Within the clinical intervention studies included in this review, several confounding factors need to
be considered when interpreting the results. For example, since it is unethical to withhold AD children
AD treatment with emollients and/or topical steroids, most studies provided treatment simultaneously
with the dietary intervention. However, not all trials reported the amount and frequency of topical
steroid use and, therefore, it is not clear if children in the treatment group were using the same amount
of topical steroids as in the control groups. Within future studies, the method of randomisation,
as well as amount and frequency of used topical steroids, should be reported. Although in some
trials a decrease of local steroid use was mentioned, the effect of nutritional intervention compared to
pharmacological treatment may both influence the AD severity score. For clinical outcome comparisons,
the SCORAD score is validated for AD severity, but it is known to be difficult to assess in young
infants, providing possible inter-observer variability. Moreover, due to the relapsing-remitting nature
of AD in these young children (which occurs randomly in time), this may complicate the evaluation of
AD severity and the impact of nutritional intervention effects in time. Recently, the evaluation on AD
measurements provided recommendations about scoring AD severity, providing an interesting tool for
future research. These include SIS (skin intensity score) (paediatric version), POEM (patient-oriented
eczema measure), SCORAD (Severity Scoring of Atopic Dermatitis index), SA-EASI (self-administered
eczema area and severity index score), and adapted SA-EASI, which are currently the most appropriate
instruments to assess AD and, therefore, should be recommended as core symptom instruments in
future clinical trials [59].
With the knowledge that both the child’s microbiome and mucosal immunity evolves from infancy
into early childhood, the age of inclusion in a study of AD is of utmost importance. In infants the
cheeks are a typical preferred site of AD and the nasal tip is usually spared. After one year of age,
a change of AD sites is more prone to the antecubital and popliteal fossa. Possible explanation for this
change is change in the diversity in the skin microbiome and changes in skin barrier function in early
life. Nevertheless the age of inclusion was within the dietary intervention studies, which may explain
the differing results. Hypothesizing that the first year of life is the essential period for programming the
mucosal immune system, this may also be the preferred time to prevent the development of AD with
microbial modulations. However, as shown within some recent meta-analyses with a specific focus
on the clinical evidence from dietary intervention studies, it was concluded that dietary intervention
during pregnancy, or lactation in the mothers, or in the early life of the infant led to a decreased risk
of AD development, but not the development of other allergies [60–62]. It should be noted that the
overall evidence is low due to the inconsistent results among studies. In order to investigate and
understand the mechanisms involved in immune modulation capacities of microbiota by dietary
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interventions on clinical outcome severity of AD in childhood, the consistency between trials must
increase. Therefore, criteria should be formulated on how to conduct future studies in this field in
order to be able to compare clinical trial outcomes, so that subsequently reliable and valid advice can
be given to implement dietary interventions in the management of AD.
5. Conclusions
Identifying high-risk children for atopic manifestations and AD children who can benefit
from these microbial modulations seems highly relevant. Moreover, a better understanding of the
contributing factors, such as the skin microbiome, faecal composition, and biomarkers of skin barrier
function, leading to changes within serum biomarker profiles would be of great value for a more
individualized therapeutic approach in AD management in children. In addition, to overcome the
problem of heterogeneity of the studies and therefore the limitation of comparing clinical trial outcomes,
an international committee of experts should focus on definitions of outcome measures, treatment
duration, administration of the product, etc. Since the development and evolution of each child’s
microbiome starts from infancy up to childhood, an early life dietary intervention (in pregnancy
and/or in infancy) seems preferable. Further standardized clinical research is, however, necessary to
gain more insight into specific strains, prebiotics and timing for optimal intervention. By combining
the individual factors of a child with AD, as mentioned above, it may be possible to eventually match
the clinical needs with the best dietary management option available.
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